206 related articles for article (PubMed ID: 18922110)
1. A novel CXCR4 antagonist for hematopoietic stem cell mobilization.
Fricker SP
Expert Opin Investig Drugs; 2008 Nov; 17(11):1749-60. PubMed ID: 18922110
[TBL] [Abstract][Full Text] [Related]
2. Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.
Steinberg M; Silva M
Clin Ther; 2010 May; 32(5):821-43. PubMed ID: 20685493
[TBL] [Abstract][Full Text] [Related]
3. Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells.
Uy GL; Rettig MP; Cashen AF
Expert Opin Biol Ther; 2008 Nov; 8(11):1797-804. PubMed ID: 18847313
[TBL] [Abstract][Full Text] [Related]
4. HIF-1α is required for hematopoietic stem cell mobilization and 4-prolyl hydroxylase inhibitors enhance mobilization by stabilizing HIF-1α.
Forristal CE; Nowlan B; Jacobsen RN; Barbier V; Walkinshaw G; Walkley CR; Winkler IG; Levesque JP
Leukemia; 2015 Jun; 29(6):1366-78. PubMed ID: 25578474
[TBL] [Abstract][Full Text] [Related]
5. Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil™) and potential of other CXCR4 antagonists as stem cell mobilizers.
De Clercq E
Pharmacol Ther; 2010 Dec; 128(3):509-18. PubMed ID: 20826182
[TBL] [Abstract][Full Text] [Related]
6. Diabetes Limits Stem Cell Mobilization Following G-CSF but Not Plerixafor.
Fadini GP; Fiala M; Cappellari R; Danna M; Park S; Poncina N; Menegazzo L; Albiero M; DiPersio J; Stockerl-Goldstein K; Avogaro A
Diabetes; 2015 Aug; 64(8):2969-77. PubMed ID: 25804941
[TBL] [Abstract][Full Text] [Related]
7. PIM1 inhibition effectively enhances plerixafor-induced HSC mobilization by counteracting CXCR4 upregulation and blocking CXCL12 secretion.
Müller TA; Pennisi S; Zwick A; Decker S; Klein C; Rister B; Rudorf A; Kissel S; Follo M; Wäsch R; Illert AL; Pfeifer D; Oostendorp R; Waskow C; Dierks C; Duyster J
Leukemia; 2019 May; 33(5):1296-1301. PubMed ID: 30816332
[No Abstract] [Full Text] [Related]
8. Plerixafor: a peripheral blood stem cell mobilizer.
Kessans MR; Gatesman ML; Kockler DR
Pharmacotherapy; 2010 May; 30(5):485-92. PubMed ID: 20411999
[TBL] [Abstract][Full Text] [Related]
9. Characterization of hematopoietic stem cell subsets from patients with multiple myeloma after mobilization with plerixafor.
Taubert I; Saffrich R; Zepeda-Moreno A; Hellwig I; Eckstein V; Bruckner T; Ho AD; Wuchter P
Cytotherapy; 2011 Apr; 13(4):459-66. PubMed ID: 21077729
[TBL] [Abstract][Full Text] [Related]
10. GPC-100, a novel CXCR4 antagonist, improves in vivo hematopoietic cell mobilization when combined with propranolol.
Sukhtankar DD; Fung JJ; Kim MN; Cayton T; Chiou V; Caculitan NG; Zalicki P; Kim S; Jo Y; Kim S; Lee JM; Choi J; Mun S; Chin A; Jang Y; Lee JY; Kim G; Kim EH; Huh WK; Jeong JY; Seen DS; Cardarelli PM
PLoS One; 2023; 18(10):e0287863. PubMed ID: 37878624
[TBL] [Abstract][Full Text] [Related]
11. Plerixafor (Mozobil) alone to mobilize hematopoietic stem cells from multiple myeloma patients for autologous transplantation.
Flomenberg N; Comenzo RL; Badel K; Calandra G
Biol Blood Marrow Transplant; 2010 May; 16(5):695-700. PubMed ID: 20067838
[TBL] [Abstract][Full Text] [Related]
12. Viagra Enables Efficient, Single-Day Hematopoietic Stem Cell Mobilization.
Smith-Berdan S; Bercasio A; Rajendiran S; Forsberg EC
Stem Cell Reports; 2019 Nov; 13(5):787-792. PubMed ID: 31607567
[TBL] [Abstract][Full Text] [Related]
13. Influence of a dual-injection regimen, plerixafor and CXCR4 on in utero hematopoietic stem cell transplantation and engraftment with use of the sheep model.
Goodrich AD; Varain NM; Jeanblanc CM; Colon DM; Kim J; Zanjani ED; Hematti P
Cytotherapy; 2014 Sep; 16(9):1280-93. PubMed ID: 25108653
[TBL] [Abstract][Full Text] [Related]
14. Update on clinical experience with AMD3100, an SDF-1/CXCL12-CXCR4 inhibitor, in mobilization of hematopoietic stem and progenitor cells.
Pusic I; DiPersio JF
Curr Opin Hematol; 2010 Jul; 17(4):319-26. PubMed ID: 20473162
[TBL] [Abstract][Full Text] [Related]
15. SDF-1/CXCR4 blockade to mobilize hematopoietic progenitor cells from the placenta.
Jing D; Alakel N; Bornhäuser M; Ehninger G; Ordemann R
Bone Marrow Transplant; 2010 Nov; 45(11):1661-2. PubMed ID: 20173795
[No Abstract] [Full Text] [Related]
16. New agents in HSC mobilization.
Domingues MJ; Nilsson SK; Cao B
Int J Hematol; 2017 Feb; 105(2):141-152. PubMed ID: 27905003
[TBL] [Abstract][Full Text] [Related]
17. Plerixafor for stem cell mobilization: the current status.
Bilgin YM; de Greef GE
Curr Opin Hematol; 2016 Jan; 23(1):67-71. PubMed ID: 26554889
[TBL] [Abstract][Full Text] [Related]
18. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
Nademanee AP; DiPersio JF; Maziarz RT; Stadtmauer EA; Micallef IN; Stiff PJ; Hsu FJ; Bridger G; Bolwell BJ
Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613
[TBL] [Abstract][Full Text] [Related]
19. Parathyroid hormone is a DPP-IV inhibitor and increases SDF-1-driven homing of CXCR4(+) stem cells into the ischaemic heart.
Huber BC; Brunner S; Segeth A; Nathan P; Fischer R; Zaruba MM; Vallaster M; Theiss HD; David R; Gerbitz A; Franz WM
Cardiovasc Res; 2011 Jun; 90(3):529-37. PubMed ID: 21245057
[TBL] [Abstract][Full Text] [Related]
20. New agents for mobilizing peripheral blood stem cells.
Greinix HT; Worel N
Transfus Apher Sci; 2009 Aug; 41(1):67-71. PubMed ID: 19615944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
